CCS1477 is a novel drug in Phase I/II clinical trials to treat late stage prostate cancer, haematological malignancies as well as tumours with specific drivers (AR, MYC, or p300/CBP mutations). Based on the early data to date, CellCentric has gained further funding from Morningside Venture Investments to expand its clinical evaluation programme. Over 10 hospital sites are active in the UK, with clinical operations coming on board into the US, and then Europe early 2021.
p300/CBP are twin histone acetyltransferases that act as critical co-regulators of transcriptional networks relevant to cancer. CellCentric is the first company to have developed a drug against p300/CBP, which is now being used in patients. CCS1477 is formulated as a capsule taken orally. It has been in clinical trials for over a year. With the new funding, the evaluation will expand, investigating CCS1477 both as a monotherapy and in combination with standard of care agents, for multiple specific applications. The aim is to achieve initial clinical proof of concept for more than one setting by Q2 2021.
Dr Will West, CellCentric’s CEO said ‘We are delighted with the continued clinical, commercial and investor interest in our first-in-class cancer drug, CCS1477. Many thanks to Morningside for their continued support, as we progress our clinical plans fully resourced’.
CellCentric is a development stage biotechnology company focused on a first-in-class p300/CBP bromodomain inhibitor drug, CCS1477, to treat specific cancers. The company investigated over 50 potential epigenetic-related drug targets, before focusing on the twin histone acetyl transferases p300/CBP. An earlier programme, based on an arginine methyltransferase target, was licenced to Takeda Pharmaceuticals.
CellCentric is a privately held business, with Morningside Venture Investments as its lead investor. It is UK based (Cambridge; Manchester; Oxford), but with multiple international operations and collaborations.